Investor Access Guide: How to Invest in Somatus Stock

• Qualified investors may seek exposure to Somatus pre-IPO via private secondaries, SPVs, or managed exposure.
• Access generally follows a process of: Eligibility check → demand/inventory match → issuer consent/ROFR → docs → closing and transfer.
• It’s important to remember that investing in private securities can be speculative and risky.

Most people cannot buy Somatus stock the way they purchase public stocks or ETFs. To buy private stock in Somatus before IPO, you generally need to qualify as an accredited investor or eligible entity under U.S. securities rules (plus any additional requirements specific to a given deal). To understand how these rules work in practice and why they exist, see our guide on Regulation D: accredited investors — who qualifies and why it matters.

At a high level:

• Individuals (U.S.)
  • Typically need to meet income or net-worth tests (e.g., high, sustained earnings or $1M+ net worth excluding primary residence).
  • Certain professional credentials (e.g., Series 7, 65, or 82) or “knowledgeable employee” status at a fund can also help qualify.
  • See our guide: Accredited Investor: Definition, Requirements & How to Qualify (link) for details.
• Entities (trusts, LLCs, funds, corporations)
  • May qualify if they have sufficient assets (e.g., $5M+ in investments) or if all equity owners are accredited investors.
  • Family offices and other structured vehicles may have tailored paths if they meet asset and sophistication tests.
• Jurisdiction & geography
  • Some offerings are limited to U.S. investors; others may accept certain international investors.
  • State/country rules, tax considerations, and offering exemptions all matter. Not every investor can invest in pre-IPO companies like Somatus.
• Information access
  • Expect less public information than with listed stocks.
  • Financials, cap table details, and risk factors are typically shared in private offering or deal documents, not in daily filings or earnings calls.

Note: This page is informational and not an offer to buy or sell securities. See disclosures below.

There isn’t just one way to invest in Somatus pre-IPO. In practice, access usually comes through a handful of private-market paths that depend on:

• Whether there are sellers (employees, early investors, funds).
• Whether the company allows transfers.
• Whether you’re working through a platform, fund, or direct relationship.

Comparison of access paths

Below is a high-level comparison of common ways investors invest in private company shares like Somatus before a potential IPO.

It can be challenging to find access and complete a lengthy manual deal process to purchase private security on your own. Still, a modern platform like Augment helps tame that complexity and makes the process simple.

Here’s how it works when you buy Somatus’s stock through a tech-enabled private-markets platform like Augment:

1. Check eligibility
   • Complete an onboarding flow to verify accredited status and pass KYC/AML checks.
   • Once verified, you can see more details on potential ways to invest in Somatus when inventory exists.
   • Augment offers Collective SPV Funds and direct marketplace transfers.
2. Tell us you’re interested
   • Indicate interest in Somatus, share your approximate check size, investor type (individual/entity), and jurisdiction.
   • This helps determine whether you might access private shares of Somatus through a direct secondary, an SPV, or a fund.
3. Match demand with potential supply
   • Augment will provide an allocation in one of our funds or match you to a third-party seller.
   • In some cases, you may join a waitlist until enough investor demand or seller interest accumulates.
4. Issuer consent and rights of first refusal (ROFR)
   • For secondary transfers, Somatus may have the right to approve or block transfers, or to buy the shares itself.
5. Sign documents and fund
   • When the deal moves forward, you review and sign definitive documents (purchase agreements, SPV docs, fund LPAs, etc.).
   • You then fund via wire/ACH/escrow, following the provided instructions and deadlines.
6. Closing and transfer
   • Upon closing, shares are transferred to the company’s cap table or via the transfer agent/custodian.
   • Your Augment Portfolio updates your records to reflect your position or SPV/fund interest.

When you invest in private company shares in companies like Somatus, pricing and costs work very differently from those in the public markets.

• Pricing
  • There is no public quote for Somatus stock. Prices are negotiated between buyers and sellers or set in an issuer-led event.
  • Quoted prices can shift between soft interest and closing, especially if market sentiment toward pre-IPO companies changes.
• Minimums
  • Direct secondary blocks or fund allocations can have relatively large minimum ticket sizes.
  • SPVs and feeder vehicles can sometimes let you buy private stock in Somatus with a smaller check, though still above typical public-market minimums.
  • We, at Augment, have minimums as low as $10k.
• Platform/vehicle fees
  • SPVs and funds may charge management fees, carried interest, and admin expenses.
  • Marketplace or platform fees may apply, depending on the structure and entity (details are provided in the offering documents, not on a generic page like this).
  • Augment has competitive pricing with 0/0 SPVs.
• Other costs
  • You may encounter escrow fees, wire fees, or transfer-agent charges; specifics vary by deal and service provider.
  • Tax treatment also differs from public trades and depends on your personal situation.

Compared with buying a listed stock in a brokerage app, investing in Somatus involves more steps, more paperwork, and more bespoke economics. That’s precisely why a specialized, tech-enabled platform like Augment, which tracks eligibility, documents, and status in one place, can make such a difference.

Private markets can be exciting, but they’re not magic. If you buy Somatus stock, you should be ready for the downside, not just the upside.

• Illiquidity
  • You may not be able to sell for years, or ever, even if your thesis changes.
  • There is no guarantee of future secondary liquidity or an IPO.
• Transfer restrictions
  • Contracts, company bylaws, and investor agreements often give Somatus and existing investors rights of first refusal or transfer vetoes.
  • These can slow, alter, or completely block your ability to sell.
• Information gaps
  • Private companies are not required to publish the same level of financial and operational detail as public companies.
  • You may see periodic updates, but not quarterly earnings calls or real-time filings.
• Valuation risk
  • Negotiated private valuations can be wrong—for better or worse.
  • A future IPO or exit may never validate the price you paid; down rounds and flat outcomes happen.
• Deal risk
  • Even late-stage deals can collapse over legal issues, company decisions, or shifting market conditions.
  • Until the transaction closes and the transfer is recorded, your exposure is not guaranteed.
• Regulatory and jurisdiction limits
  • Some investors and geographies may be off-limits, regardless of wealth or interest.
  • Securities rules are complex; platforms and issuers must decline to accept investors who don’t qualify under the applicable exemptions.

Understanding these risks is part of being the kind of investor regulators expect when they allow you to invest in pre-IPO companies like Somatus.